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Prion diseases, or transmissible spongiform enceph-
alopathies (TSEs), are associated with the conforma-
tional conversion of the cellular prion protein, PrPC,
into a protease-resistant form, PrPSc. Here, we
show that mutation-induced thermodynamic stabili-
zation of the folded, a-helical domain of PrPC has a
dramatic inhibitory effect on the conformational con-
version of prion protein in vitro, as well as on the
propagation of TSE disease in vivo. Transgenic
mice expressing a human prion protein variant with
increased thermodynamic stability were found to
be much more resistant to infection with the TSE
agent than those expressing wild-type human prion
protein, in both the primary passage and three
subsequent subpassages. These findings not only
provide a line of evidence in support of the protein-
only model of TSEs but also yield insight into the
molecular nature of the PrPC/PrPSc conformational
transition, and they suggest an approach to the treat-
ment of prion diseases.
INTRODUCTION
Transmissible spongiform encephalopathies (TSEs) are a group
of neurodegenerative disorders that include Creutzfeldt-Jakob
disease in humans, scrapie in sheep, chronic wasting disease
in cervids, and bovine spongiform encephalopathy in cattle
(Aguzzi and Polymenidou, 2004; Caughey et al., 2009; Cobb
and Surewicz, 2009; Collinge, 2001; Prusiner, 1998; Weissmann,
2004). The prion hypothesis asserts that the transmission of
TSEs does not require nucleic acids, and that the infectious
TSE agent is proteinaceous in nature, consisting of a misfolded248 Cell Reports 4, 248–254, July 25, 2013 ª2013 The Authorsform of prion protein (PrP) (Prusiner, 1982). Once heretical, this
protein-only model is now supported by a growing body of evi-
dence, most notably due to the recent success in generating in-
fectious prions in vitro from brain-derived (Castilla et al., 2005;
Deleault et al., 2007) or bacterially expressed (Kim et al., 2010;
Legname et al., 2004; Makarava et al., 2010; Wang et al., 2010)
PrP. However, the mechanisms involved in the conformational
conversion of the normal (cellular) PrP (denoted PrPC) to the
misfolded conformer (denoted PrPSc) remain largely unknown,
hindering our understanding of the molecular basis of prion dis-
eases as well as the development of therapeutic approaches.
Cellular human PrPC is a glycoprotein that consists of an un-
structured N-terminal region and a folded C-terminal domain
comprised of three a helices and two very short b strands
(Zahn et al., 2000). Conversion of this protein to an abnormal
PrPSc isoform occurs by a posttranslational process involving a
major conformational change that results in an increased pro-
portion of b structure (Caughey et al., 1991; Pan et al., 1993).
Although the three-dimensional structure of PrPSc remains un-
known, a body of evidence suggests that this conformational
transition involves at least partial refolding of the helix-rich
C-terminal domain (Cobb et al., 2007; Govaerts et al., 2004;
Smirnovas et al., 2011). This, together with recent findings that
mutations that reduce the thermodynamic stability of PrPC
greatly increase the propensity of PrPC to undergo a conversion
to oligomeric b-sheet forms in vitro (Apetri et al., 2005; Vanik and
Surewicz, 2002), prompted us to search for amino acid substi-
tutions that stabilize the native a-helical structure, with the
expectation that, if the protein-only hypothesis is correct, such
mutations should suppress the PrPC/PrPSc conversion and
thus attenuate replication of the infectious prion agent.
RESULTS AND DISCUSSION
A particularly dramatic increase in thermodynamic stability of
PrPC was found upon replacement of valine (V) at position 209
Figure 1. Effect of the V209MMutation on theBiophysical Properties
of Human PrP
(A) GdmCl-induced equilibrium unfolding for wild-type (WT) full-length human
PrP (HuPrP23-231) and the V209M variant. The unfolding curves were ob-
tained in 50 mM phosphate buffer, pH 7.
(B) Time-dependent transition ofWTHuPrP90-231 and the V209M variant from
a-helical structure to b-sheet oligomers as monitored by circular dichroism
spectroscopy. Spectra were recorded in 50 mM sodium acetate, pH 4, in the
absence of the denaturant and at different time points after the addition of 1 M
GdmCl. The spectrumof thea-helicalmonomer showsacharacteristic ‘‘double
minimum’’ at210 and 220 nm, whereas the spectrum of b-sheet oligomers is
characterized by lower intensity and a broad minimum around 215 nm.
(C) Time course of amyloid fibril formation forWTHuPrP and the V209M variant
as monitored by thioflavine T fluorescence. Data for both full-length protein
(HuPrP23-231) and HuPrP90-231 are shown. The lag phases (mean ± SD)
based on three to four experiments are 6.5 ± 0.5 and 16.3 ± 1.4 hr for
HuPrP23-231 and V209MHuPrP23-231, respectively, and 18 ± 2 and 42 ± 3 hr
for HuPrP90-231 and V209M HuPrP90-231, respectively. See also Figure S1.withmethionine (M). As shown in Figure 1A, equilibrium unfolding
of the full-length wild-type recombinant human PrP (HuPrP23-
231) in guanidinium chloride (GdmCl) at pH 7 is characterized
by a midpoint unfolding GdmCl concentration of 2.1 M and a
free-energy difference between the native and unfolded states,
DGo, of 20.6 kJ/mol. For the V209M variant, the unfolding curve
is shifted to much higher denaturant concentrations (midpoint at
2.8 M) and the DGo value is increased to 31.9 kJ/mol. A similar
effect was observed for N-truncated HuPrP90-231, with DGO
increasing from 20.9 to 30.0 kJ/mol. The observed increase of
10 kJ/mol in the free energy of unfolding is remarkably high
and, to the best of our knowledge, is among the largest reported
for a single residue mutation in any protein. Thermodynamic sta-
bilization of the native PrP structure by the Val209/Met substi-
tution was further confirmed by thermal unfolding experiments
using differential scanning calorimetry (Figure S1).
It was previously shown that under mildly acidic conditions in
the presence of low concentrations of GdmCl, the N-truncated
recombinant HuPrP90-231 undergoes a transition to an oligo-
meric b-sheet structure mimicking certain properties of PrPSc
(Apetri et al., 2005; Vanik and Surewicz, 2002). Under the presentexperimental conditions (sodium acetate buffer, pH 4, 1 M
GdmCl, protein concentration of 24 mM), the a-helix/b-sheet
transition for the wild-type HuPrP90-231 was completed within
60 min. In contrast, the V209M mutant was highly resistant to
this conversion, remaining in a monomeric a-helical form even
after 12 hr of incubation under identical conditions (Figure 1B).
Incubation of the recombinant PrP in the presence of GdmCl
at neutral pH is known to result in the formation of thioflavine
T-positive amyloid structures with fibrillar morphology (Apetri
et al., 2005; Baskakov, 2004). Under the present experimental
conditions, the conversion to amyloid fibrils for the wild-type
HuPrP23-231 was characterized by a lag phase of 6.5 ± 0.5 hr.
Again, upon replacement of Val209 with Met, this reaction
became much slower, with an increased lag phase of 16.3 ±
1.4 hr (Figure 1C). For the N-truncated HuPrP90-231, the conver-
sion reactions were slower compared with the full-length protein.
However, also in this case the V209M mutation reduced the rate
of the conversion reaction (lag phase of 18 ± 2 and 42 ± 3 hr for
wild-type HuPrP90-231 and V209M HuPrP90-231, respectively;
Figure 1C). Collectively, these data demonstrate that the V209M
mutation greatly increases the thermodynamic stability of PrPC,
resulting in a remarkably reduced propensity of the protein to un-
dergo a conversion to PrPSc-mimicking, b-sheet-rich aggregates
in vitro.
An inspection of nuclear magnetic resonance (NMR) data indi-
cates that the structure of wild-type human PrP (Zahn et al.,
2000) is characterized by the presence of three cavities (PDB
ID: 1QM0). Two of these cavities (with volumes of 57 and 14 A˚3
and surface areas of 76 and 29 A˚2) are surrounded by residues
of the second and third a-helices and the loops connecting
a-helix 1 with b strands 1 and 2 (Figure 2). The third cavity
(18 A˚3, 34 A˚2) is located at the packing interface of helices 1
and 3. The presence of such cavities within the hydrophobic
core of proteins is known to have a destabilizing effect (Eriksson
et al., 1992). Our initial modeling suggested that the substitution
of Met in place of Val 209 should largely eliminate the cavities in
PrP, providing a rationale for improved thermodynamic stability.
This prediction was verified by the NMR-determined structure
(Figures 2 and S2; Table S1). Indeed, as shown in Figure 2, the
structure of the V209M variant shows remarkably improved
packing within the hydrophobic core, resulting in a complete
removal of the two larger cavities near residue 209. This is a
consequence of the different side-chain geometry of residue
209 and subtle changes in the packing and geometry of helices
1 and 3. Apart from this minor difference, the overall fold of the
mutant protein remains unaltered.
To test whether thermodynamic stabilization of the folded
domain of PrP is sufficient to confer resistance to prion replica-
tion in vivo, we created two lines of transgenic mice in the Friend
Virus B (FVB)/PrP null background: one expressing wild-type
human PrP [denoted Tg(HuPrP)] and the other expressing the
superstable variant [denoted Tg(HuPrPV209M)]. Western blot
analysis indicates that both lines of transgenic mice express
PrP in the brain at a level similar to that observed for wild-
type FVB mice, and with comparable electrophoretic profiles
dominated by the diglycosylated form (Figures 3A and 3C). Con-
focal microscopy of primary neurons derived from Tg(HuPrP)
and Tg(HuPrPV209M) mice (Figure 3B), as well as of humanCell Reports 4, 248–254, July 25, 2013 ª2013 The Authors 249
Figure 3. Transmission of CJD Prions in Tg(HuPrP) and
Tg(HuPrPV209M) Mice
(A) PrP expression levels in brains of Tg(HuPrP), Tg(HuPrPV209M), and WT FVB
mice as probed by western blotting using mAb 8H4.
(B) Cell-surface and intracellular localization of PrP in primary neurons pre-
pared from Tg(HuPrPV209M) and Tg(HuPrP) mice. Cells were probed for PrP
with mAb 3F4, counterstained for nuclei with Hoechst, and examined with a
confocal microscope. Scale bars: 10 mm.
(C) PrPSc in brains of sCJDMM1-infected Tg(HuPrP) and Tg(HuPrPV209M) mice.
Transgenic mice were intracerebrally inoculated with brain homogenate from a
subject with sCJDMM1. Brain homogenates from symptomatic mice and the
inoculum (Inoc) were subjected to western blot analysis with mAb 3F4 before
() and after (+) PK treatment.
(D) Spongiform degeneration in brains of sCJDMM1-infected Tg(HuPrP)
and Tg(HuPrPV209M) mice. Fixed brain sections from cerebral cortex of
Tg(HuPrPV209M) mice show small and scattered areas with vacuoles (circled
area), whereas in Tg(HuPrP) mice spongiform degeneration is much more
widespread and severe. Brain sections were stained with hematoxylin and
eosin. Scale bars: 100 mm. See also Figure S3.
Figure 2. NMR-Determined Structures—Ribbon Representations—
of the PrP Folded Domain
(A) Wild-type human PrP (Zahn et al., 2000; PDB ID: 1QM0).
(B) The V209M variant of human PrP. In theWT protein, two cavities (displayed
as white spheres) are present near residue V209. In the V209M variant, these
cavities are eliminated as a result of altered side-chain geometry of residue 209
and subtle changes in the packing and geometry of helices a1 and a3. A third
cavity of nearly equal size in both proteins is found near Pro 158 between
helices a2 and a3. Side chains surrounding the cavities are shown and labeled
with residue numbers. The structure shown for the V209M variant represents
the lowest-energy structure of the ensemble of 20 water-refined conformers.
Additional structural details and statistics are provided in Figure S2 and
Table S1.
250 Cell Reports 4, 248–254, July 25, 2013 ª2013 The Authorsneuroblastoma cell line M17 transfected with either wild-type
human PrP (HuPrP) or the V209M variant (HuPrPV209M) (data
not shown), demonstrates that HuPrP and HuPrPV209M have
similar cellular distributions, residing both at the cell surface
and in intracellular compartments. Furthermore, treatment of
M17 cells expressing PrPV209M with phosphatidylinositol-spe-
cific phospholipase C (PI-PLC) released HuPrPV209M into the cul-
ture medium, indicating that, like wild-type PrP, PrPV209M is
attached to the cell membrane by a glycosylphosphatidylinositol
(GPI) anchor (Figure S3). Together, these data indicate that
Tg(HuPrP) and Tg(HuPrPV209M) mice express comparable
amounts of PrP, and that the cellular localization of PrPV209M is
indistinguishable from that of the wild-type protein.
After intracerebral inoculation with brain homogenates derived
from subjects with sporadic Creutzfeldt-Jacob disease (sCJD),
Table 1. Primary and Secondary Transmissions of sCJD in Transgenic Mice
Tg Line Inoculum Attack Rate Incubation Time (Days)a Titers (ID50 U/g)
Tg(HuPrP) sCJDMM1b 9/9 263 ± 13 4.6 3 107
sCJDMM2b 9/9 267 ± 17 3.2 3 107
Tg(HuPrPV209M) sCJDMM1 2/6 685, 696
sCJDMM2 0/7 R798
Tg(HuPrP) Tg(HuPrPV209M)-passaged sCJDMM1 5/5 316 ± 16 8.3 3 105
Tg(HuPrPV209M) Tg(HuPrPV209M)-passaged sCJDMM1 6/6 431 ± 30
Tg(HuPrP) sCJDMM1 passaged twice in Tg(HuPrPV209M) 7/7 267 ± 12c
Tg(HuPrPV209M) sCJDMM1 passaged twice in Tg(HuPrPV209M) 7/7 366 ± 18e
Tg(HuPrP) sCJDMM1 passaged thrice in Tg(HuPrPV209M) 10/10 295 ± 7c
Tg(HuPrPV209M) sCJDMM1 passaged thrice in Tg(HuPrPV209M) 4/6d 399 ± 6e
See also Figure S4.
aAverage values and SEMs are shown.
bThe MM1 and MM2 subtypes of sCJD according to the classification of Parchi et al. (1999).
cThe difference in incubation times between the third and fourth passages in Tg(HuPrP) mice is statistically insignificant (p = 0.11).
dTwo mice are still alive with no apparent symptoms (at 580 days postinoculation).
eThe difference in incubation times between the third and fourth passages in Tg(HuV209MPrP) mice is statistically insignificant (p = 0.28).all inoculated Tg(HuPrP) mice fell ill after an incubation time of
263 days (Table 1), exhibiting classical symptoms of TSE dis-
ease. In sharp contrast, only two of six sCJDMM1-inoculated
Tg(HuPrPV209M) mice (and none of seven sCJDMM2-inoculated
Tg(HuPrPV209M) mice) became symptomatic after a very long in-
cubation time of nearly 700 days (Table 1). As expected, western
blot analysis revealed that the brains of all inoculated Tg(HuPrP)
mice accumulated relatively large quantities of proteinase K
(PK)-resistant PrP, PrPSc, which electrophoretically reproduced
the pattern of the original sCJD PrPSc (Figure 3C). In contrast,
PrPSc was found in the brains of only two symptomatic
Tg(HuPrPV209M) mice, but not in the remaining 11 symptom-
free animals, even after sodium phosphotungstate precipitation
treatment of brain homogenate to enrich PrPSc (Safar et al.,
1998). The electrophoretic profile of PrPSc from the two infected
Tg(HuPrPV209M) mice differed from that of Tg(HuPrP) mice with
regard to gel mobility and the ratio of bands representing
different PrPSc glycoforms (Figure 3C). Furthermore, compared
with the inoculated Tg(HuPrP) mice, the two affected
Tg(HuPrPV209M) mice displayedmuch less severe overall spongi-
form neurodegeneration, reduced PrP immunostaining, and
significantly different lesion profiles (Figures 3D and S4A–S4D).
Altogether, these data indicate that, compared with transgenic
mice expressing wild-type human PrP, Tg(HuPrPV209M) mice
are more resistant to infection with sCJD prions. However, the
question must be raised as to whether the enhanced resistance
of Tg(HuPrPV209M) mice is intrinsic or due to the ‘‘mutation
barrier’’ related to the mismatch in the amino acid sequence
between the wild-type sCJD PrPSc of the inoculum and the
mutated PrPV209M expressed by the recipient Tg(HuPrPV209M)
mice.
The availability of two sCJD-affected Tg(HuPrPV209M) mice
provided us with the opportunity to probe this question by per-
forming a second passage experiment. Upon inoculation with
the Tg(HuPrPV209M)-adapted sCJD preparations (which con-
tained only the newly generated PrPSc(V209M) isoform), all of the
Tg(HuPrP) mice (which express wild-type PrPC) became infectedwith an average incubation of 316 days, which is longer than
the 263 days of incubation needed after inoculation of the
original (not passaged) sCJD preparation (Table 1). This increase
in incubation time most likely can be attributed to the mutation
barrier now existing between the PrPV209M of the inoculum and
the PrPC expressed by the recipient Tg(HuPrP) mice. Remark-
ably, despite the lack of any mutation barrier between the
inoculum and Tg(HuPrPV209M) mice in this second-passage
experiment, the Tg(HuPrPV209M) mice required a much longer in-
cubation of431 days, although this time all of them succumbed
to the disease (Table 1). Because the passage of prions in
mutant mice might be associated with the strain adaptation phe-
nomenon (Bartz et al., 2000), we performed two additional pas-
sages. Although the incubation time in the third passage in
Tg(HuPrPV209M) mice decreased from 431 to 366 days, no further
reduction in the incubation time was observed in the fourth
passage, indicating that the adaptation process had been
completed. Importantly, even at this point, the incubation time
was still much longer for Tg(HuPrPV209M) mice than for Tg(HuPrP)
mice (366 and 399 days versus 267 and 295 days in the third and
fourth passages, respectively; Table 1). Thus, these data clearly
demonstrate an inherently high resistance of Tg(HuPrPV209M)
mice to sCJD prion infection.
Intriguingly, second- to fourth-passage Tg(HuPrP) mice inoc-
ulated with PrPSc(V209M) were characterized by PrPSc electropho-
retic patterns and lesion profiles that were indistinguishable from
those observed in the first passage experiment with sCJD-inoc-
ulated Tg(HuPrP) mice, whereas distinct electrophoretic charac-
teristics of PrPSc(V209M) and lesion profiles were consistently
maintained in passages in Tg(HuPrPV209M) mice (Figures S4C–
S4E). These data strongly suggest that the PrPSc isoforms asso-
ciatedwith the V209Mmutation can be faithfully propagated only
in the host containing this mutation, whereas in Tg(HuPrP) mice
they ‘‘adapt back’’ to the characteristics apparently dictated by
the wild-type PrP host.
Tg(HuPrPV209M) mice were specifically generated to test
whether thermodynamic stabilization of the folded domain ofCell Reports 4, 248–254, July 25, 2013 ª2013 The Authors 251
PrPC as observed in vitro is sufficient to inhibit prion replication
in vivo. The answer to this question is clearly yes, providing a
line of evidence in support of the protein-only model of TSEs.
While the requirement for PrPC in TSE pathogenesis has been
demonstrated in seminal experiments with PrP-knockout mice
(Bu¨eler et al., 1993), the present data show that this requirement
is directly related to the ability of PrPC to undergo a conversion to
the PrPSc state, and that prion propagation in vivo can be effec-
tively inhibited by stabilizing the normal a-helical conformation of
PrPC. Given the similar electronic and hydrophobic properties of
Val and Met residues, it is highly unlikely that the reduced con-
version propensity of the mutant protein is due to factors other
than thermodynamic stabilization. Furthermore, since residue
209 is buried within the hydrophobic interior of the protein, its
substitution should not affect the interaction of PrPC with other
cellular cofactors in vivo.
The finding that thermodynamic stabilization of the native
a-helical domain of PrPC inhibits prion propagation in mice im-
pacts the ongoing debate regarding critical yet still unresolved
issues in prion research: the mechanism of PrP conversion and
the structure of the infectious PrPSc conformer. Although some
models postulate that the C-terminal region of PrPSc retains at
least partial native a-helical structure of PrPC (DeMarco and
Daggett, 2004; Govaerts et al., 2004), recent data indicate that
PrP conversion involves major refolding of the entire C-terminal
region, and that this region in PrPSc consists of b strands and
short turns/loops, with no a helices present (Smirnovas et al.,
2011). The present finding is consistent with the latter scenario,
providing strong support to the notion that PrP conversion in vivo
involves a major rearrangement of the a-helical domain of PrPC.
Finally, the present data suggest a strategy for pharmaco-
logical intervention in prion diseases. Although a number of
immuno- and chemotherapeutic approaches have been pro-
posed (Cashman and Caughey, 2004), there is currently no
effective treatment for TSEs. A promising new strategy has
recently emerged, based on the downregulation of PrPC expres-
sion using small interfering RNA (Pfeifer et al., 2006). However,
this approach may carry significant risks given the reported
role of PrPC in cell signaling, neuroprotection, and other physio-
logical processes (Westergard et al., 2007). The finding that one
can effectively reduce prion replication in vivo by stabilizing the
native conformation of PrPC without manipulating its expression
level offers an alternative and potentially more practical strategy
based on screening and/or rational design of small molecules
that can thermodynamically stabilize the normal conformation
of monomeric PrPC. Recently, a generally similar approach
was successfully used to develop a clinically effective drug
against transthyretin amyloidosis, even though in the latter
case the stabilization is kinetic rather than thermodynamic, pre-
venting dissociation of the transthyretin tetramer (Bulawa et al.,
2012).EXPERIMENTAL PROCEDURES
Protein Purification
Recombinant human PrP 90-231 (HuPrP90-231) and the V209M mutant (both
129M variants) were prepared and purified as described previously (Apetri
et al., 2005). Uniformly 15N- and 13C/15N-labeled proteins for NMR spectros-252 Cell Reports 4, 248–254, July 25, 2013 ª2013 The Authorscopy were expressed in Escherichia coli using a minimal medium containing
13C6 glucose (3 g/l) and/or
15N NH4Cl (1 g/l) as the sole carbon and nitrogen
sources, respectively.
Biophysical Experiments
Equilibrium unfolding experiments were performed with the use of circular
dichroism spectroscopy (50 mM phosphate buffer, pH 7) by monitoring
GdmCl-induced changes in ellipticity at 220 nm as described previously (Ape-
tri et al., 2005). The unfolding curves were analyzed using a two-state transition
model (Santoro and Bolen, 1988). The conversion of PrP variants to b-sheet
oligomers was performed in 50 mM sodium acetate buffer containing 1 M
GdmCl, pH 4, and monitored by circular dichroism spectroscopy as described
previously (Apetri et al., 2005). The concentration of each protein in these ex-
periments was 24 mM. The conversion of the proteins to amyloid fibrils at
neutral pH (50 mM phosphate buffer, 1.5 M GdmCl, pH 7, protein concentra-
tion of 30 mM) was performed and monitored by thioflavine T assay as
described previously (Apetri et al., 2005).
Structural Studies
The structure of V209M human PrP was determined by NMR spectroscopy.
Details of these experiments are provided in Extended Experimental
Procedures.
Transgenic Mice
HuPrP and HuPrPV209M transgene constructs were based on the murine half-
genomic PrP clone (HGPRP) (Fischer et al., 1996). Tg40, a Tg(HuPrP) line
that expresses wild-type human PrP-129M at the same level as the murine
PrP in wild-type FVB mice, was described previously (Kong et al., 2005).
Tg(HuPrPV209M) mice were created in the same fashion and bred with FVB/
Prnp0/0mice to obtain Tg(HuPrPV209M)Prnp0/0mice. The transgene expression
in brain was examined by western blotting analysis using monoclonal antibody
(mAb) 3F4 or 8H4 as described below. Tg20, a Tg(HuPrPV209M) line expressing
the mutant PrP at the wild-type FVBmouse level, was used for all transmission
experiments. All transgenic mice used were in the Prnpo/o background.
Inoculation and Examination of Transgenic Mice
Frozen brain tissues from human subjects with sCJD or prion-infected trans-
genic mice were homogenized in PBS and inoculated intracerebrally into the
brains of Tg(HuPrP) and Tg(HuPrPV209M) mice as previously described (Kong
et al., 2005). Thirty microliters of 1% brain homogenate was injected into
each animal. Prion symptoms were monitored as previously described
(Kong et al., 2005) and the animals were sacrificed within 2–3 days after the
appearance of symptoms. Each brain was sliced sagittally; half was frozen
for western blot analysis (see below) and half was fixed in formalin for staining
with hematoxylin and eosin or anti-PrP antibody 3F4 (Castellani et al., 1996;
Kong et al., 2005). The prion titers of the sCJD or mouse brain tissues were
calculated according to the incubation time using a previously described
method based on endpoint titration of sCJDMM1 in Tg40 mice (Prusiner
et al., 1982).
Western Blotting Analysis and Detection of PK-Resistant PrP
Total protein concentrations of brain homogenates in the lysis buffer (100 mM
Tris, 150 mM NaCl, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 10 mM
EDTA, pH 7.8) were measured with BCA Protein Assay Reagents (Thermo
Fisher Scientific). Total PrP and PK-resistant PrPSc were examined by western
blotting using precast SDS-PAGE gels with 8H4 or 3F4 antibodies in conjunc-
tion with horseradish-peroxidase-conjugated goat anti-mouse IgG Fc anti-
body essentially as described previously (Pan et al., 2001). PK digestion was
performed for 1 hr at 37C using 100 mg/ml of the enzyme.
Confocal Immunofluorescence Imaging of Primary Neurons
Primary cortical neuron cultures were prepared from day 14–16 embryos of
Tg(HuPrP) and Tg(HuPrPV209M) mice (Yuan et al., 2008). Cell-surface and intra-
cellular PrP was examined with a Zeiss LSM510 inverted confocal microscope
using mAb 3F4 and goat anti-mouse IgG (H+L) conjugated with highly cross-
absorbed Alexa Fluor 488 (Invitrogen) as described previously (Mishra et al.,
2002).
ACCESSION NUMBERS
The coordinates and structural restraints for V209M HuPrP have been depos-
ited under BMRB accession number 19268, RCSB ID code rcsb103353, and
PDB ID code 2M8T.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, four
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.celrep.2013.06.030.
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